Procathepsin D as a tumor marker, anti-cancer drug or screening agent

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 172-175

  Vetvicka, Vaclav ^a   Fusek, Martin ^b  

^a University of Louisville School of Medicine   (United States)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Antibodies; Aspartic; Autoantibodies; Breast; Cancer; Cathepsin D; Drug; Enzyme; Marker; Procathepsin D; Proteinase; Screening; Treatment; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; PROCATHEPSIN D; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER THERAPY; HUMAN; METASTASIS; TUMOR GROWTH; TUMOR VOLUME;

EID: 84856276319     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012799014904     Document Type: Article

References (41)

1. Hasilik, A.; Neufeld. E.F. Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J. Biol. Chem., 1980, 255, 4937-4945.
2. Hasilik, A.; Neufeld, E.F. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J. Biol. Chem., 1980, 255, 4946-4950.
3. Fortenberry, S.C.; Schorey, J.S.; Chirgwin, J.M. Role of glycosylation in the expression of human procathepsin D. J. Cell Sci., 1995, 108, 2001-2006.
4. Kornfeld, S. Lysosomal enzyme targeting. Biochem. Soc. Trans., 1990, 18, 367-374.
5. von Figura, K.; Hasilik, A. Lysosomal enzymes and their receptors. Annu. Rev. Biochem., 1986, 55, 167-193.
6. Reid, W.A., Valor, M.; Kay, J. Immunolocalization of cathepsin D in normal and neoplastic tissues. J. Clin. Pathol., 1986, 39, 1323-1330.
7. Briozzo, P.; Badet, J.; Capony, F.; Pieri, I.; Montcurrier, P.H.; Barritault, D.; Rochefort, H. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp. Cell Res., 1991, 194, 252-259.
8. Berchem, G.; Glondu, M.; Gleizes, M.; Brouilett, J.P.; Vignon, F.; Garcia, M.; Liaudet-Coopman, E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002, 21, 5951-5955.
9. Laurent-Matha, V.; Maruani-Herrmann, S.; Prébois, C.; Beaujouin, M.; Glondu, M.; Noël, A.; Avarez-Gonzalez, M. L.; Blacher, S.; Coopman, P.; Baghdiguian, S.; Gilles, C.; Loncarek, J.; Freiss, G.; Vignon, F.; Liaudet-Coopman, E. Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J. Cell Biol., 2005, 168, 489-99.
10. Nomura, T.; Katunuma, N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest., 2005, 52,1-9.
11. Rodriguez, J.; Vazquez, J.; Corte, M.D.; Lamelas, M.; Bongera, M.; Corte, M.G.; Alvarez, A.; Allende, M.; Gonzalez, L.; Sanchez, M.; Vijande, M.; Garcia-Muniz, J.; Vizoso, F. Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int. J. Biol. Markers 2005, 20, 103-111.
12. Huet, G.; Zerimech, F.; Dieu, M.C.; Hemon, B.; Gerard, G.; Balduyck, M.; Janin, A.; Lafyatis, R.; Degand, P.; Dieu, M.C.; Janin, A., Lafyatis R. The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator. Int. J. Cancer 1994, 57, 875-882.
13. Lah, T.T.; Calaf, G.; Kalman, E.; Shinde, B.G.; Russo, J.; Jarosz, D.; Zabrecky, J.; Somers, R.; Daskal, I. Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). Biol. Chem. Hoppe-Seyler 1995, 376, 357-363.
14. Tedone, T.; Correale, M.; Barborossa, G.; Casavole, V.; Paradiso, A.; Reshkin, S.J. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J., 1997, 11, 785-792.
15. Benes, P.; Vetvicka, V.; Fusek, M. Cathepsin D - Many functions of one aspartic protease. Crit. Rev. Oncol. Hematol., 2008, 68, 12-28.
16. Westley, B.R.; May, F.E.B. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleid Acid Res., 1987, 15, 3773-3786.
17. Thorpe, S.M.; Rochefort, H.; Garcia, M.; Freiss, G.; Christensen, I.J.; Khalaf, S.; Paolucci, F.; Pau, B.; Rasmussen, B.B.; Rose, C. Association between high concentration of 52,000 MW cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 1989, 49, 6008-6014.
18. Harding, C.; Osundeko, O.; Tetlow, L.; Faragher, E.B.; Howell, A.; Bundred, N.J. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br. J. Canc., 2000, 82, 354-360.
19. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P; Taube, S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25, 5287-5312.
20. Fusek, M.; Vetvicka, V. Mitogenic function of human procathepsin D - role of the activation peptide. Biochem. J., 1994, 303, 775-780.
21. Beaujouin, M., Prebois, C., Derocoq, D., Laurent-Matha, V., Masson, O., Pattingre, S., Coopman, P., Bettache, N., Grossfield, J., Hollingsworth, R. E., Zhang, H., Yao, Z., Hyman, B. T., van der Geer, P., Smith, G. K.; Liaudet-Coopman, E. Pro-cathepsin D interacts with the extracellular domain of the β chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J. Cell Sci., 2010, 123, 3336-3346.
22. Garcia, M.; Derocq, D.; Pujol, P.; Rochefort, H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5, 1809-1814.
23. Vashishta; A.; Ohri, S. S.; Proctor, M.; Fusek, M.; Vetvicka, V. Role of activation peptide of procathepsin D in proliferation and invasion of lung cancer cells. Anticancer Res., 2006, 26(6B), 4163-4170.
24. Sivaparvathi, M.; Sawaya, R.; Chintala, S.K., Go, Y.; Gakaslan, Z.L.; Rao, J.S. Expression of cathepsin D during the progression of human gliomas. Neurosci. Lett., 1996, 208, 171-174.
25. Ohri, S.S.; Vashishta, A.; Proctor. M.; Fusek. M.; Vetvicka. V. Depletion of procathepsin D gene expression by RNA interference: A potential therapeutic target for breast cancer. Cancer Biol. Ther., 2007, 6, 1081-1087.
26. Vashishta, A.; Ohri, S.S.; Proctor, M.; Fusek, M., Vetvicka, V. Ribozyme-targeting procathepsin D and its effect on invasion and growth of breast cancer cells: an implication in breast cancer therapy. Int. J. Oncol., 2007, 30, 1223-1230.
27. Vetvicka, V.; Benes, P.; Fusek, M. Procathepsin D in breast cancer: what do we know? Effects of ribozymes and other inhibitors. Cancer Gene Ther., 2002, 9, 854-863.
28. Glondu, M.; Liaudet-Coopman, E.; Derocq, D.; Platet, N.; Rochefort, H.; Garcia, M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene, 2002, 21, 5127-5134.
29. Vetvicka, V.; Vetvickova, J.; Hilgert, I.; Voburka, Z.; Fusek, M. Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int. J. Cancer, 1997, 73, 403-409.
30. Vetvicka, V., Vetvickova, J. and Fusek, M. Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development. Breast Cancer Res. Treat., 1999, 57, 261-269.
31. Vetvicka, V.; Vetvickova, J.; Fusek, M. Role of procathepsin D activation peptide in prostate cancer growth. Prostate, 2002, 44, 1-7.
32. Liaudet-Coopman, E.; Beaujouin, M.; Derocq, D.; Garcia, M.; Glondu-Lassis, M.; Laurent-Matha, V.; Prebois, C.; Rochefort, H.; Vignon, F. 29, protease in cancer and apoptosis. Cancer Lett., 2006, 237, 167-179.
33. Fusek, M.; Vetvickova, J.; Vetvicka, V. Secretion of cytokines in breast cancer cells: the molecular mechanism of pCD proliferative effects. J. Interferon Cytokine Res., 2007, 27, 191-199.
34. Beaujouin, M.; Baghdiguian, S.; Glondu-Lassis, M.; Berchem, G.; Liaudet-Coopman, E. Overexpression of both catalytically active and inactive cathepsin D by cancer cells enhances apoptosisdependent chemo-sensitivity. Oncogene 2006, 25, 1967-1973.
35. Sagulenko, V.; Muth, D.; Sagulenko, E.; Paffhausen, T.; Schwab, M.; Westermann, F. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis 2008, 29, 1869-1877.
36. Bazzett, L.B.; Watkins, C.S.; Gercel-Taylor, C.; Taylor, D.D. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gyn. Oncol., 1999, 74, 181-187.
37. Hara, I.; Miyake, H.; Yamanaka, K.; Hara, S.; Kamidono, S. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Oncol. Rep., 2002, 9, 1379-1383.
38. Skrzydlewska, E.; Sulkowska, M.; Wincewicz, A.; Koda, M.; Sulkovski, S. Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer. World J. Gastroenterol., 2005, 11, 4225-4229.
39. Wozniak, A.; Mila-Kierzenkowska, C.; Schachtschabel, D. O.; Wozniak, B.; Rozwodowska, N.; Drewa, T., Drewa, S.; Sir, J., Sir, I.; Maciak, R.; Krzyzynska-Malinowska, E. Activity of cathepsin D and alpha (1)-antitrypsin in the blood serum of patients with mammary carcinoma. Exp. Oncol., 2005, 27, 233-237.
40. Vashishta, A.; Ohri S.; Vetvickova, J.; Fusek, M.; Ulrichova, J.; Vetvicka, V. Procathepsin D secreted by HaCaT keratinocyte cells - A novel regulator of keratinocyte growth. Eur. J. Cell. Biol., 2007, 86, 303-313.
41. Jeffery, C.J. Moonlighting proteins: old proteins learning new tricks. TRENDS in Genetics, 2003, 19, 415-417.